- Home
- EPAM vs ELAN Comparison
EPAM vs ELAN Comparison
Compare EPAM & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPAM | ELAN |
|---|---|---|
| Founded | 1993 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.3B |
| IPO Year | 2011 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EPAM | ELAN |
|---|---|---|
| Price | $140.63 | $24.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | ★ $201.07 | $27.63 |
| AVG Volume (30 Days) | 1.5M | ★ 4.3M |
| Earning Date | 05-22-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.72 | N/A |
| Revenue | $1,450,448,000.00 | ★ $4,715,000,000.00 |
| Revenue This Year | $8.92 | $6.83 |
| Revenue Next Year | $8.87 | $5.26 |
| P/E Ratio | $20.76 | ★ N/A |
| Revenue Growth | ★ 25.02 | 6.22 |
| 52 Week Low | $125.57 | $8.02 |
| 52 Week High | $222.53 | $27.72 |
Technical Indicators
Market Signals| Indicator | EPAM | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 32.71 | 48.05 |
| Support Level | N/A | $23.72 |
| Resistance Level | $165.67 | $25.68 |
| Average True Range (ATR) | 8.58 | 0.94 |
| MACD | -0.75 | -0.03 |
| Stochastic Oscillator | 22.77 | 31.26 |
Price Performance
Historical ComparisonAbout EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.